Teva Pharmaceutical Industries (TEVA) Non-Current Debt (2009 - 2026)

Teva Pharmaceutical Industries (TEVA) has reported Non-Current Debt for 18 consecutive years, with $12.1 billion the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Non-Current Debt fell 27.86% year-over-year to $12.1 billion; the trailing twelve-month figure through Jun 2026 stood at $12.1 billion (down 27.86% YoY), and the FY2025 full-year result was $15.0 billion, down 6.35% from the prior year.
• Non-Current Debt fell to $12.1 billion in Q2 2026 per TEVA's latest filing, from $14.0 billion in the prior quarter.
• Across five years, Non-Current Debt topped out at $20.8 billion in Q1 2022 and bottomed at $12.1 billion in Q2 2026.
• Historically, Non-Current Debt has averaged $17.2 billion across 5 years, with a median of $16.8 billion in 2025.
• The sharpest annual moves came in 2025 and 2026: Non-Current Debt climbed 2.23% in 2025, then declined 27.86% in 2026.
• Over 5 years, Non-Current Debt stood at $19.1 billion in 2022, then declined by 4.93% to $18.2 billion in 2023, then retreated by 11.89% to $16.0 billion in 2024, then dropped by 6.35% to $15.0 billion in 2025, then retreated by 19.31% to $12.1 billion in 2026.
• According to Business Quant data, Non-Current Debt over the past three periods registered $12.1 billion, $14.0 billion, and $15.0 billion for Q2 2026, Q1 2026, and Q4 2025 respectively.